Quick answers
- What is Methylergonovine maleate used for?
- The FDA-approved label (Methylergonovine Maleate, Granules Pharmaceuticals Inc., October 8, 2026) says: “Following delivery of the placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Methylergonovine maleate?
- The “Adverse Reactions” section of the FDA label (Methylergonovine Maleate, Granules Pharmaceuticals Inc., October 8, 2026) begins: “Clinical trials experience Common Adverse Reactions The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension has also been reported. Abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Methylergonovine maleate?
- The “Drug Interactions” section of the FDA label (Methylergonovine Maleate, Granules Pharmaceuticals Inc., October 8, 2026) begins: “CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Methylergonovine maleate have a boxed warning?
- No. None of the 14 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Methylergonovine maleate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Methylergonovine maleate been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started June 16, 2026 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Methylergonovine maleate?
- 13 companies list prescription products of Methylergonovine maleate in the FDA NDC Directory, including Bryant Ranch Prepack, HF Acquisition Co LLC, DBA HealthFirst and Pharmacist Pharmaceutical, LLC.
What Methylergonovine maleate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Following delivery of the placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder.
— FDA label: Methylergonovine Maleate, Granules Pharmaceuticals Inc., effective October 8, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (tablet, oral), Methylergonovine Maleate, Granules Pharmaceuticals Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 14 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 14 FDA labels for this medicine have a boxed warning.
Methylergonovine maleate side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
Clinical trials experience Common Adverse Reactions The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension has also been reported. Abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally.
Read more of this section
Rare Adverse Reactions Rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. There have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. Post marketing Experience The following adverse drug reactions have been derived from post-marketing experience with methylergonovine maleate via spontaneous case reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Nervous system disorders Cerebrovascular accident, paraesthesia Cardiac disorders Ventricular fibrillation, ventricular tachycardia, angina pectoris, atrioventricular block
— FDA label: Methylergonovine Maleate, Granules Pharmaceuticals Inc., effective October 8, 2026. Read the full label on DailyMed →
Methylergonovine maleate drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
Read more of this section
Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. Weak CYP 3A4 inhibitors should be administered with caution. Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine. CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. Concomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids. Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. Glyceryl trinitrate and other antianginal drugs Methylergonovine maleate produces vasoconstriction and can be expected to reduce the effect of glyceryl trinitrate and other antianginal drugs. No pharmacokinetic interactions involving other cytochrome P450 isoenzymes are known. Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins.
— FDA label: Methylergonovine Maleate, Granules Pharmaceuticals Inc., effective October 8, 2026. Read the full label on DailyMed →
Methylergonovine maleate dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Orally The recommended dosage of Methylergonovine Maleate is One tablet, 0.2 mg, orally 3 or 4 times daily in the puerperium for a maximum of 1 week.
— FDA label: Methylergonovine Maleate, Granules Pharmaceuticals Inc., effective October 8, 2026. Read the full label on DailyMed →
Methylergonovine maleate in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Use of Methylergonovine Maleate is contraindicated during pregnancy because of its uterotonic effects. (See INDICATIONS AND USAGE) Animal reproductive studies have not been conducted with Methylergonovine Maleate. It is not known whether Methylergonovine Maleate can cause fetal harm or can affect reproductive capacity.
— FDA label: Methylergonovine Maleate, Granules Pharmaceuticals Inc., effective October 8, 2026. Read the full label on DailyMed →
Methylergonovine maleate and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
Mothers should not breast-feed during treatment with methylergonovine maleate and at least 12 hours after administration of the last dose. Milk secreted during this period should be discarded. Methylergonovine Maleate may produce adverse effects in the breast-feeding infant. Methylergonovine Maleate may also reduce the yield of breast milk
— FDA label: Methylergonovine Maleate, Granules Pharmaceuticals Inc., effective October 8, 2026. Read the full label on DailyMed →
When Methylergonovine maleate should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Hypertension; toxemia; pregnancy; and hypersensitivity.
— FDA label: Methylergonovine Maleate, Granules Pharmaceuticals Inc., effective October 8, 2026. Read the full label on DailyMed →
Methylergonovine maleate overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
Symptoms of acute overdose may include: nausea, vomiting, oliguria, abdominal pain, numbness, tingling of the extremities, rise in blood pressure, in severe cases followed by hypotension, respiratory depression, hypothermia, convulsions, and coma. Because reports of overdosage with methylergonovine maleate are infrequent, the lethal dose in humans has not been established. The oral LD 50 (in mg/kg) for the mouse is 187, the rat 93, and the rabbit 4.5.
Read more of this section
Several cases of accidental methylergonovine maleate injection in newborn infants have been reported, and in such cases 0.2 mg represents an overdose of great magnitude. However, recovery occurred in all but one case following a period of respiratory depression, hypothermia, hypertonicity with jerking movements, and convulsions. Also, several children 1 to 3 years of age have accidentally ingested up to 10 tablets (2 mg) with no apparent ill effects. A postpartum patient took 4 tablets at one time in error and reported paresthesias and clamminess as her only symptoms. Treatment of acute overdosage is symptomatic and includes the usual procedures of: 1. removal of offending drug by inducing emesis, gastric lavage, catharsis, and supportive diuresis. 2. maintenance of adequate pulmonary ventilation, especially if convulsions or coma develop. 3. correction of hypotension with pressor drugs as needed. 4. control of convulsions with standard anticonvulsant agents. 5. control of peripheral vasospasm with warmth to the extremities if needed.
— FDA label: Methylergonovine Maleate, Granules Pharmaceuticals Inc., effective October 8, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Tablet · Injection · Injection, solution |
|---|---|
| Route | Oral · Intravenous · Intramuscular |
| Prescription products | 15 in the FDA NDC Directory |
| Brand names | Methergine |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| methylergonovine maleate 0.2 mg tablet | Generic | $5.07 per tablet |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack2 products
- HF Acquisition Co LLC, DBA HealthFirst2 products
- Pharmacist Pharmaceutical, LLC1 product
- Rising Pharma Holdings, Inc.1 product
- Amneal Pharmaceuticals NY LLC1 product
- Breckenridge Pharmaceutical, Inc.1 product
- Volley Pharmaceuticals, LLC1 product
- American Health Packaging1 product
- Lupin Pharmaceuticals, Inc.1 product
- American Regent, Inc.1 product
- Major Pharmaceuticals1 product
- Granules Pharmaceuticals Inc.1 product
- Teva Pharmaceuticals USA, Inc.1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (8)
- ANDA090193Am Regent · November 24, 2008
- ANDA040889Breckenridge · September 13, 2010
- ANDA091577Chartwell Rx · May 2, 2011
- ANDA210424Granules · May 15, 2018
- ANDA211483Amneal Pharms · September 10, 2018
- ANDA211455Teva Pharms USA · March 20, 2019
- ANDA212233Tp Anda Holdings · May 1, 2020
- ANDA211919Rising · January 15, 2021
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
June 16, 2026 · Class II · Ongoing · D-0609-2026
Subpotent Drug
Carton Label: MAJOR, Methylergonovine Maleate Tablets, USP, 0.2 mg, 20 TABLETS (2 x 10), Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, in 46268, NDC 0904-7282-10. Blister Label: Methylergonov — The Harvard Drug Group LLC
-
March 25, 2024 · Class II · Completed · D-0477-2024
Failed Dissolution Specifications
Methylergonovine Maleate Tablets, USP, 0.2mg, 12-count bottle, Rx Only, Distributed by: Amneal Pharmaceuticals, LLC, Bridgewater, NJ 08807, NDC # 69238-1605-2. — Amneal Pharmaceuticals of New York, LLC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 996824, 996826, 996828 |
|---|---|
| SPL set ID of the quoted label | b49b1e4c-de20-446d-b80a-75c7f0d41ddf |
| FDA labels (SPL) | 14 |
| FDA applications | 8 ANDA |
| Active ingredients (FDA) | METHYLERGONOVINE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- MethergineBrand page: products, maker and price
- Bryant Ranch PrepackMaker or distributor
- HF Acquisition Co LLC, DBA HealthFirstMaker or distributor
- Pharmacist Pharmaceutical, LLCMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Methylergonovine Maleate, Granules Pharmaceuticals Inc., effective October 8, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →